Archive · 6 Jan 2026
India Introduces New Bulk Drug Licensing Scheme
India is making new rules for companies that make important medicines.
They want to make sure these companies are responsible for what they sell.
The government has already set a minimum price for some medicines that are imported, especially from China.
This is to help Indian companies make these medicines themselves.
The government has also given money to Indian companies to start making these medicines.
They have already started 34 projects to make 25 different kinds of medicines.
India plans to introduce a new bulk drug licensing regime to regulate imports in the crucial sector.
A supplier database will be created to fix accountability in the supply chain.
The government has implemented a minimum import price (MIP) on certain bulk drugs, APIs, and intermediates.
Indian companies have started manufacturing APIs under the government's production-linked incentive (PLI) scheme.
48 projects have been selected under the PLI scheme, with 34 commissioned for 25 bulk drugs.
- Who
- Indian government
- What
- Introduction of a new bulk drug licensing regime and supplier database
- When
- Not specified
- Where
- India
- Why
- To regulate imports, support domestic manufacturing, and curb cheap imports, especially from China
- New Licensing Scheme
- India plans to introduce a new bulk drug licensing regime.
- Supplier Database
- A supplier database will be created to fix accountability.
- Minimum Import Price (MIP)
- MIP implemented on certain bulk drugs, APIs, and intermediates.
- Production-Linked Incentive (PLI) Scheme
- Launched in 2020 with a financial outlay of ₹6,940 crore.
- Projects Under PLI Scheme
- 48 projects selected, 34 commissioned for 25 bulk drugs.
